NuLife Sciences, Inc.

Company Overview

NuLife Sciences Inc. is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including wound care, organ and tissue transplants, regenerative medicine, and cell therapy. NuLife Sciences Inc. operates through two wholly-owned subsidiaries, NuLife Medical and NuLife BioMed. NuLife Medical utilizes a patent protected and unique proprietary method referred to as the "NuLife Technique" for the treatment of chronic wounds that resist closure or healing, such as diabetic foot ulcers and abrasions. NuLife Medical is currently applying the treatment to trial patients in Latin America with the goal of expanding globally, and into the United States. NuLife BioMed focuses on advancing human organ transplant technology that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. NuLife BioMed utilizes the NuLife Technique and is currently in preclinical trials involving animal studies on its pathway to commercialization. The Company also seeks opportunities to acquire, merge or develop with other technologies with a focus on changing and saving lives. For more information please visit www.nulifesciences.us.

NuLife Sciences Inc. owns the following subsidiaries:

  • NuLife Medical Utilizes a patent protected and unique proprietary method referred to as the "NuLife Technique" for the treatment of chronic wounds that resist closure or healing, such as diabetic foot ulcers and abrasions.
  • NuLife BioMed - Established to focus on advancing human organ transplant technology based on the NuLife Technique process, which could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs.

Investor Relations Overview

Latest Financial Results

Q2 2017

Quarter Ended Mar 31, 2017

Latest 10-K

For Fiscal Year 2016

Download 10-K

Stock Information

Symbol

OTCQB: NULF

Price

Change

Volume

52 week Low/High

Day Low/High

Contact Information

Investor Relations

MZ Group
Ted Haberfield
President - MZ North America
T: 760-755-2716
M: 858-204-5055
thaberfield@mzgroup.us
www.mzgroup.us

Transfer Agent

Direct Transfer, LLC.
500 Perimeter Park Drive
Suite D
Morrisville, NC 27560
T: 918-481-4000
ts@issuerdirect.com
www.issuerdirect.com